Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acedoben (also known as 4-acetamidobenzoic acid) is a benzoic acid derivative and a metabolite of benzocaine. It is primarily used as a component of the immunomodulatory drug inosine pranobex (inosine acedoben dimepranol), which is indicated for the treatment of mucocutaneous infections due to herpes simplex virus types 1 and/or II. It also serves as adjunctive therapy for genital warts in combination with podophyllin or carbon dioxide laser and is used in subacute sclerosing panencephalitis. Acedoben itself acts as an immunomodulator when part of this combination; it does not have direct antiviral activity but contributes to immune system modulation[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acedoben.